Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory, and antiviral agents

Medicinal Research Reviews

Volumn 23, Issue 5, 2003, Pages 535-558

  Supuran, Claudiu T ^a   Casini, Angela ^a   Scozzafava, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anticancer; Antiinflammatory agents; Antiviral; Caspase; Cathepsin; HCMV; HIV; HNE; HSV; Matrix metalloprotease; Sulfonamide; TACE

Indexed keywords

2 (N BENZYL 4 METHOXYBENZENESULFONAMIDO) N HYDROXY 3 METHYLBUTANAMIDE; AMINO ACID DERIVATIVE; AMPRENAVIR; ARYLSULFONIC ACID DERIVATIVE; CARBONATE DEHYDRATASE; CASPASE; CATHEPSIN; CGS 27023A; CYSTEINE PROTEINASE; DIURETIC AGENT; HYDROXAMIC ACID DERIVATIVE; INDISULAM; ISOENZYME; LEUKOCYTE ELASTASE INHIBITOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PROTEINASE INHIBITOR; STROMELYSIN; SULFONAMIDE; THIOL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTHRITIS; BACTERIAL MENINGITIS; BRAIN INJURY; CANCER INVASION; CHRONIC BRONCHITIS; CYSTIC FIBROSIS; DRUG STRUCTURE; DRUG SYNTHESIS; EMPHYSEMA; ENTERITIS; HERPES VIRUS; HYPOGLYCEMIA; INFLAMMATION; ISCHEMIA; PATHOPHYSIOLOGY; PROTEINASE INHIBITION; REPERFUSION INJURY; RESPIRATORY DISTRESS; REVIEW; RHEUMATOID ARTHRITIS; STROKE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; MODELS, CHEMICAL; PROTEASE INHIBITORS; SULFONAMIDES;

EID: 0041919643     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10047     Document Type: Review

References (81)

1. Drew J. Drug discovery: A historical perspective. Science 2000;287:1960-1964.
2. Supuran CT. Indisulam. IDrugs 2002;5:1075-1079.
3. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-189.
4. Supuran CT, Scozzafava A. Applications of carbonic anhydrase inhibitors and activators in therapy. Exp Opin Ther Patents 2002;12:217-242.
5. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors. Curr Med Chem-Imm Endoc Metab Agents 2001;1:61-97.
6. Maren TH. Relations between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 1976;16:309-327.
7. Supuran CT, Conroy CW, Maren TH. Carbonic anhydrase inhibitors. Synthesis and inhibitory properties of 1,3,4-thiadiazole-2,5-bissulfonamide. Eur J Med Chem 1996;31:843-846.
8. Boyd AE. Sulfonylurea receptors, ion channels and fruit flies. Diabetes 1988;37:847-850.
9. Thornber CW. Isosterism and molecular modification in drug design. Chem Soc Rev 1979;8:563-580.
10. Ogden RC, Flexner CW, editors. Protease Inhibitors in AIDS Therapy. New York, Basel: Marcel Dekker, 2001.
11. Supuran CT, Scozzafava A, Clare BW. Bacterial protease inhibitors. Med Res Rev 2002;22:329-372.
12. Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors. Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of carbonic anhydrase isozymes I, II and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000; 43:3677-3687.
13. Wouters J, Michaux C, Durant F, Dogné JM, Delarge J, Masereel B. Isosterism among analogues of torasemide: Conformational, electronic and lipophilic properties. Eur J Med Chem 2000;35:923-929.
14. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999;3:500-509.
15. Lehnert M. Clinical multidrug resistance in cancer: A multifactorial problem. Eur J Cancer 1996;6:912-920.
16. Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst 2000;92:898-902.
17. Jones DA, Fitzpatrick FA. Genomics and the discovery of new drug targets. Curr Opin Chem Biol 1999; 3:71-76.
18. Condra JH, Miller MD, Hazuda DJ, Emini EA. Potential new therapies for the treatment of HIV-1 infection. Annu Rev Med 2002;53:541-555.
19. Vella S, Palmisano L. Antiretroviral therapy: State of the HAART. Antiviral Res 2000;45:1-7.
20. Joly V, Yeny P. New trends in antiretroviral therapy of HIV infection. Eur J Int Med 2000;11:301-308.
21. Supuran CT, Scozzafava A. Matrix metalloproteinases (MMPs). In: Smith HJ, Simons C, editors. Proteinase and peptidase inhibition: Recent potential targets for drug development. London, New York: Taylor & Francis, 2002, pp 35-61.
22. Woessner JF, Nagase H. Matrix metalloproteinases and TIMPs. Oxford: Oxford University Press, 2000, pp 1-223.
23. MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, Zhu L, Hu S, Melton RA, Fryer L, Goldberg RL, Doughty JR, Spirito S, Blancuzzi V, Wilson D, O'Byrne EM, Ganu V, Parker DT. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997;40:2525-2532.
24. Whittaker M, Floyd CD, Brown P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999;99:2735-2776.
25. 2′ pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett 1999;9:1691-1696.
26. Scozzafava A, Supuran CT. Protease inhibitors. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating N-4-nitrobenzylsulfonyl glycine hydroxamate moieties. J Med Chem 2000;43:1858-1865.
27. Clare BW, Scozzafava A, Supuran CT. Protease inhibitors: Synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type. J Med Chem 2001;44:2253-2258.
28. Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Oba K, Kaneko T, Syouji T, Igarashi A, Nakamura S. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. Jpn J Cancer Res 2001;92:688-695.
29. Pikul S, McDow Dunham K, Almstead NG. Heterocycle-based MMP inhibitors with P2′ substituents. Bioorg Med Chem Lett 2001;11:1009-1013.
30. Baxter AD, Bhogal R, Bird J. Arylsulphonyl hydroxamic acids: Potent and selective matrix metalloproteinase inhibitors. Bioorg Med Chem Lett 2001;11:1465-1468.
31. Barta TE, Becker DP, Bedell LJ. Selective, orally active MMP inhibitors with an aryl backbone. Bioorg Med Chem Lett 2001;11:2481-2483.
32. Levin JI, Gu Y, Nelson FC. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett 2001;11:239-242.
33. Schroder J, Henke A, Wenzel H. Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. J Med Chem 2001;44:3231-3243.
34. Dankwardt SM, Martin RL, Chan CS. Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase: Solid-phase synthesis of omithine analogues. Bioorg Med Chem Lett 2001;11: 2085-2088.
35. Casini A, Scozzafava A, Supuran CT. Sulfonamide derivatives with protease inhibitory action as anticancer, antiinflammatory and antiviral agents. Exp Opin Ther Patents 2002;12:1307-1327.
36. Black RA. Tumor necrosis factor-α converting enzyme. Int J Biochem Cell Biol 2002;34:1-5.
37. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733.
38. Moss ML, White JM, Lambert WH, Andrews RC. TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today 2001;6:417-426.
39. Gomis-Ruth X, Meyer E, Kress LF, Politi V. Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor-α convertase inhibitors. Protein Sci 1998;7:283-292.
40. Barlaam B, Bird T, van der Brempt LC, Campbell D, Foster SJ, Makiewicz R. New α-substituted succinate-based TNF-α convertase inhibitors. J Med Chem 1999;42:4890-4908.
41. Chen JM, Jin G, Sung A, Levin JI. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1′ groups. Bioorg Med Chem Lett 2002;12:1195-1198.
42. Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1′ group. Bioorg Med Chem Lett 2002;12:1199-1202.
43. Letavic MA, Axt MZ, Barberia JT, Carty TJ, Danley DE, Geoghegan KF, Halim NS, Hoth LR, Kamath AV, Laird ER, Lopresti-Morrow LL, McClure KF, Mitchell PG, Natarajan V, Noe MC, Pandit J, Reeves L, Schulte GK, Snow SL, Sweeney FJ, Tan DH, Yu CH. Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitors. Bioorg Med Chem Lett 2002;12: 1387-1390.
44. Edwards PD. Human neutrophil elastase inhibitors. In: Smith HJ, Simons C, editors. Proteinase and peptidase inhibition - Recent potential targets for drug development. London, New York: Taylor & Francis, 2002, pp 154-177.
45. An-Zhi W, Mayr I, Bode W. The refined 2.3 A crystal structure of human leukocyte elastase in a complex with a valine chloromethyl ketone inhibitor. FEBS Lett 1998;234:367-373.
46. De Nanteuil G, Portevin B, Benoist A. Disease-modifying anti-ostheoarthritic drugs: Current therapies and new prospects around protease inhibition. Farmaco 2001;56:107-112.
47. Tomizawa N, Ohwada S, Ohya T. The effects of a neutrophil elastase inhibitor (ONO-5046 Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs. J Heart Lung Transplant 1999;18:637-645.
48. Kirscehnheuter GP, Oleksyszyn J, Lyle W. Synthesis and characterization of human neutrophil elastase inhibitors derived from aromatic esters of phenylalkanoic acids. Agents Act 1993;42:71-82.
49. Groutas WC, He S, Kuang R, Ruan S, Tu J, Chan HK. Inhibition of serine proteases by functionalized sulfonamides coupled to the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold. Bioorg Med Chem 2001;9: 1543-1548.
50. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-113.
51. Wilson KP, Black JF, Thomson JA. Structure and mechanism of interleukin-1 beta converting enzyme. Nature 1994;370:270-275.
52. Walker NPC, Talanian RV, Brady KD. Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: A (p20/p10)2 homodimer. Cell 1994;78:343-352.
53. Shahripour AB, Plummer MS, Lunney EA. Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide. Bioorg Med Chem Lett 2001;11:2779-2782.
54. Lee D, Long SA, Murray JH. Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem 2001;44:2015-2026.
55. Rukamp B, Powers JC. Cathepsins. In: Smith HJ, Simons C, editors. Proteinase and peptidase inhibition - Recent potential targets for drug development. London, New York: Taylor & Francis, 2002, pp 84-126.
56. Falgueyeret JP, Oballa RM, Okamoto O. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J Med Chem 2001;44:94-104.
57. De Clercq E. Antiviral drugs: Current state of the art. J Clin Virol 2001;22:73-89.
58. Richman DR. HIV chemotherapy. Nature 2001;410:995-1001.
59. De Clercq E. New developments in anti-HIV chemotherapy. Curr Med Chem 2001;8:1543-1572.
60. De Clercq E. Molecular targets for antiviral agents. J Pharmacol Exptl Ther 2001;297:1-10.
61. De Clercq E. Strategies in the design of antiviral drugs. Nature Drug Discov 2002;1:13-25.
62. Erickson JW. HIV-1 protease as a target for AIDS therapy. In: Ogden RC, Flexner CW, editors. Protease inhibitors in AIDS therapy. New York: Marcel Dekker; 2001, pp 1-25.
63. Tung RD, Livingston DJ, Rao BG. Design and synthesis of amprenavir, a novel HIV protease inhibitor. In: Ogden RC, Flexner CW, editors. Protease inhibitors in AIDS therapy. New York: Marcel Dekker; 2001, pp 101-118.
64. Chrusciel RA, Thaisrivongs S, Nicholas JA. HIV protease inhibitors in early development. In: Ogden RC, Flexner CW, editors. Protease inhibitors in AIDS therapy. New York: Marcel Dekker; 2001, pp 119-137.
65. Wlodawer A, Gustchina A. Structural and biochemical studies of retroviral proteases. Biochim Biophys Acta 2000;1477:16-34.
66. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157-162.
67. Gatell JM. From amprenavir to GW433908. J HIV Ther 2001;6:95-99.
68. Ghosh AK, Shin D, Swanson L. Structure-based design of non-peptide HIV protease inhibitor. Farmaco 2001;56:29-32.
69. Rusconi S, La Seta Catamancio S. HIV-1 protease inhibitors in development. Exp Opin Investig Drugs 2002;11:387-395.
70. Turner SR, Strohbach JW, Tommasi RA. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998;41:3467-3476.
71. Skulnick HI, Johnson PD, Aristoff PA. Structure-based design of non-peptidic HIV protease inhibitor: The sulfonamide-substituted cyclooctylpyranones. J Med Chem 1997;40:1149-1164.
72. Lee YS, Lee JY, Kim SN, Lee CK, Park H. 6-Hydroxy-1,3-dioxin-4-ones as non-peptidic HIV protease inhibitors. Bioorg Med Chem Lett 2000;10:2625-2627.
73. Dorsey BD, Vacca JP. Discovery and early development of indinavir. In: Ogden RC, Flexner CW, editors. Protease inhibitors in AIDS therapy. New York: Marcel Dekker; 2001, pp 65-83.
74. Hulten J, Bonham NM, Nillroth U, Hallberg A. Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies and computational predictions of binding affinities. J Med Chem 1997;40: 885-897.
75. Backbro K, Lowgren S, Osterlund K, Hallberg A. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J Med Chem 1997;40:898-902.
76. Hulten J, Andersson HO, Schaal W, Hallberg A. Inhibitors of the C2-symmetric HIV-1 protease: Nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2′ side chains. J Med Chem 1999;42:4054-4061.
77. Jarvest RL, Dabrowski CE. Herpes virus and cytomegalovirus proteinase. In: Smith HJ, Simons C, editors. Proteinase and peptidase inhibition - Recent potential targets for drug development. London, New York: Taylor & Francis; 2002, pp 264-281.
78. Rawlinson WD. Diagnosis of human cytomegalovirus infection and disease. Pathology 1999;31:109-115.
79. Ensoli B, Sturzl M, Monini P. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv Cancer Res 2001;81:125-159.
80. Borthwick AD, Crame AJ, Ertl PF. Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality. J Med Chem 2002;45:1-18.
81. Shieh HS, Kurumbail RG, Stevens AM. Three dimensional structure of human cytomegalovirus protease. Nature 1996;383:279-282.